Influence of Different Light Dose on the Adverse Effect of Swallowing for Esophageal Carcinoma
A Phase III Randomized Controlled Study of the Effect of Different Light Doses on Adverse Outcomes of Swallowing in Esophageal Cancer
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Background: Photodynamic therapy (PDT) is one of the effective means for the control of esophageal stenosis in advanced esophageal cancer, among which the dose intensity of laser irradiation is one of the factors affecting the efficacy. This study aims to pursue the appropriate dose of light.
Aim: To compare the efficacy and safety of two groups of different laser irradiation doses for advanced esophageal cancer and esophageal stricture.
Methods: Fifty-seven patients were recruited for this study and randomly divided into two groups: single irradiation group and reirradiation group.Single irradiation group: 46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Double irradiation group: 46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
Primary endpoints: ORR rates at 1 and 3 months, the quality of life
Undersøgelsestype
Undersøgelsestype
Tilmelding (Forventet)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Shegan Gao, MD, PhD
- Telefonnummer: 18638859977
- E-mail: gsg112258@163.com
Undersøgelse Kontakt Backup
- Navn: Tanyou Shan, MD, PhD
- Telefonnummer: 18537976669
- E-mail: shantanyoudoctor@163.com
Studiesteder
-
-
Henan
-
Luoyang, Henan, Kina, 471003
- The First Affiliated Hospital and Clinical Medicine of Henan University of Science and Technology
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- esophagus cancer
- 18-80 years old
- grade 3-4 dysphagia (Stoller classification)
- Non-eradicative second-line treatment
Exclusion Criteria:
- Ulcerative tumor
- Esophageal stenosis caused by radiotherapy
- Survival is less than 3 months
- Patients known to be allergic to photosensitizers
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: single irradiation group
46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2
|
46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2
|
|
Aktiv komparator: Double irradiation group
46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
|
46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
1 month objective response rate
Tidsramme: 1 month after photodynamic irradiation
|
Grade 3-4 dysphagia accounted
|
1 month after photodynamic irradiation
|
|
3 month objective response rate
Tidsramme: 3 month after photodynamic irradiation
|
Grade 3-4 dysphagia accounted
|
3 month after photodynamic irradiation
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
3 month Quality of Life score
Tidsramme: 3 month after photodynamic irradiation
|
3 month after photodynamic irradiation
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studiestol: Shegan Gao, MD, PhD, The First Affiliated Hospital of Clinical Medicine of Henan University of Science and Technology
- Studieleder: Tanyou Shan, MD, PhD, The First Affiliated Hospital and Clinical Medicine of Henan University of Science and Technology
- Ledende efterforsker: Caihong Dong, MD, PhD, The First Affiliated Hospital and Clinical Medicine of Henan University of Science and Technology
- Ledende efterforsker: Wanying Li, MD, The First Affiliated Hospital and Clinical Medicine of Henan University of Science and Technology
- Ledende efterforsker: Jiachun Sun, MD, PhD, The First Affiliated Hospital and Clinical Medicine of Henan University of Science and Technology
- Ledende efterforsker: Mengxi Zhang, MD, PhD, The First Affiliated Hospital and Clinical Medicine of Henan University of Science and Technology
- Ledende efterforsker: Xiaozhi Yuan, MD, PhD, The First Affiliated Hospital and Clinical Medicine of Henan University of Science and Technology
Publikationer og nyttige links
Generelle publikationer
- Zeng R, Liu C, Li L, Cai X, Chen R, Li Z. Clinical Efficacy of HiPorfin Photodynamic Therapy for Advanced Obstructive Esophageal Cancer. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820930335. doi: 10.1177/1533033820930335.
- Yoon HY, Cheon YK, Choi HJ, Shim CS. Role of photodynamic therapy in the palliation of obstructing esophageal cancer. Korean J Intern Med. 2012 Sep;27(3):278-84. doi: 10.3904/kjim.2012.27.3.278. Epub 2012 Sep 1.
- Liu H, Liu Y, Wang L, Ruan X, Wang F, Xu D, Zhang J, Jia X, Liu D. Evaluation on Short-Term Therapeutic Effect of 2 Porphyrin Photosensitizer-Mediated Photodynamic Therapy for Esophageal Cancer. Technol Cancer Res Treat. 2019 Jan 1;18:1533033819831989. doi: 10.1177/1533033819831989.
- Lee HH, Choi MG, Hasan T. Application of photodynamic therapy in gastrointestinal disorders: an outdated or re-emerging technique? Korean J Intern Med. 2017 Jan;32(1):1-10. doi: 10.3904/kjim.2016.200. Epub 2017 Jan 1.
- Yano T, Minamide T, Takashima K, Nakajo K, Kadota T, Yoda Y. Clinical Practice of Photodynamic Therapy Using Talaporfin Sodium for Esophageal Cancer. J Clin Med. 2021 Jun 24;10(13):2785. doi: 10.3390/jcm10132785.
- National Health Commission Of The People's Republic Of China. Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version). Chin J Cancer Res. 2019 Apr;31(2):223-258. doi: 10.21147/j.issn.1000-9604.2019.02.01. No abstract available.
Datoer for undersøgelser
Studer store datoer
Studiestart (Forventet)
Studiestart
Primær færdiggørelse (Forventet)
Primær færdiggørelse
Studieafslutning (Forventet)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ECPDT-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Spiserørskræft
-
NCT07331857Ikke rekrutterer endnuBarrett's esophagus (BE)
-
NCT03621319AfsluttetBarretts spiserør | Højgradig dysplasi i Barrett-esophagus | Lavgradig dysplasi i Barrett-esophagus
-
NCT07643727Ikke rekrutterer endnuBarrett Esophagus Adenocarcinom | Barrett's Esophagus With or Without Dysplasia
-
NCT04154748AfsluttetBarretts esophagus med lavgradig dysplasi
-
NCT03015571AfsluttetHeterotopisk maveslimhinde i den proksimale esophagus
-
NCT03205501AfsluttetSpiserørskræft | Barrett Esophagus | Dysplasi i Barrett Esophagus
-
NCT01124214AfsluttetBarretts esophagus, esophageal intraepithelial neoplasi
-
NCT07455422Ikke rekrutterer endnuBarrett Esophagus | Gastroenterologi | Barrett Esophagus Adenocarcinom | Adenocarcinom - GEJ | Gastroenterologisk kræft
-
NCT04054713SuspenderetIntestinal Metaplasi | Dysplasi | Barretts esophagus med lavgradig dysplasi
-
NCT06803147RekrutteringBarrett Esophagus | Barrett Esophagus Adenocarcinom
Kliniske forsøg med single irradiation
-
NCT07532824RekrutteringAkut myeloid leukæmi (AML) | Protonterapi | MDS og AML før allogen SCT | Myelodysplastisk neoplasma | Myelodysplastisk syndrom (MDS)/AML
-
NCT07332247RekrutteringTilbagevendende nasopharynx carcinom | Nasopharangeal kræft
-
NCT00589602AfsluttetLymfom | Myelodysplastiske syndromer | Leukæmi | Kroniske myeloproliferative lidelser | Præcancerøs/ikke-malign tilstand | Sekundær myelofibrose | Myelomatose og maligne plasmacelle-neoplasmer
-
NCT00416884Afsluttet
-
NCT07297914Ikke rekrutterer endnuStamcelletransplantation | Akut lymfatisk leukæmi (ALL) | Pode - Versus-værtssygdom
-
NCT02670252AfsluttetAkut lymfatisk leukæmi | Allogen hæmatopoietisk stamcelletransplantation | Busulfan | Total kropsbestråling
-
NCT00002844Afsluttet
-
NCT01247688Trukket tilbageLymfoide hæmatologiske maligniteter | Navlestrengsblodtransplantation
-
NCT07493538RekrutteringAkut myeloid leukæmi | Myelodysplastiske syndromer | AML | Akut leukæmi | MDS
-
NCT07524530Ikke rekrutterer endnuLymfom | Leukæmi | Hæmatologiske neoplasmer | Core Binding Factor Alpha Subunits